article
David Johnson of GigaGen discusses how recombinant forms of intravenous…
4 May 2020 | By Hannah Balfour (Drug Target Review)
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.